Composite of kidney failure (Figure 2)
The kidney failure composite included the following outcomes: Kidney failure, End-stage kidney disease, Sustained decrease to 15 ml/min/1.73 m2, Sustained decrease of eGFR by >40% from baseline, and death from renal causes are the criteria for renal failure. Four out of five studies [5,10,14,15] reported renal failure, and the pooled analysis revealed that treatment with Finerenone was associated with a decreased risk of renal failure compared to placebo (RR = 0.91 [0.81, 1.01] p=0.11; I2= 38%). Similarly, End stage kidney disease, Sustained decrease to 15 ml/min/1.73 m2, Sustained decrease of eGFR of >40% from baseline and death from renal causes were reported by 3 of 5 studies[5,10,14], and the pooled analysis demonstrated that treatment with Finerenone was associated with a decreased risk of the aforementioned outcomes compared to placebo (RR = 0.80 [0.69, 0.93] p=0.004; I2= 0%), (RR = 0.82 [0.72, 0.94] p=0.004; I2= 0%), (RR = 0.85 [0.80, 0.90] p <0.00001; I2= 0%) and (RR = 0.56 [0.17, 1.82] p=0.34; I2= 0%), respectively.